Hinge Therapeutics

Hinge Therapeutics is a private, early-stage biopharmaceutical company developing small-molecule therapeutics for traditionally challenging or undruggable targets. The company says its proprietary Hinge Drug Discovery Platform combines artificial intelligence, sequence and mutation analysis, conformational biology, a Hinge-focused effector library, and phenotypic assays to discover compounds that induce functional protein conformational changes. Hinge Therapeutics is pursuing programs in hemophilia and other bleeding disorders, solid tumors, cardiovascular disease, central nervous system disorders including Alzheimer's disease, rare disease, and anti-aging. The company also collaborates with Toyohashi University of Technology to commercialize ion imaging sensor technology for drug discovery and diagnostic applications. Publicly available evidence suggests the company remains at the preclinical discovery stage, with no disclosed clinical-stage assets.